LitCovid-sentences  

PMC:7195088 / 20796-22468 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T144 0-30 Sentence denotes Remdesivir Adenosine analogue.
T145 31-196 Sentence denotes It binds to RNA-dependent RNA polymerase and acts as an RNA-chain terminator • Not available • Comparison of remdesivir vs. placebo in patients with severe COVID-19.
T146 197-240 Sentence denotes Double-blind RCT (NCT04257656, recruiting).
T147 241-330 Sentence denotes Primary endpoint: clinical status, assessed by an ordinal scale at days 7, 14, 21 and 28.
T148 331-413 Sentence denotes • Comparison of remdesivir vs. placebo in patients with mild to moderate COVID-19.
T149 414-457 Sentence denotes Double-blind RCT (NCT04252664, recruiting).
T150 458-531 Sentence denotes Primary endpoint: time to clinical recovery in hours (follow-up 28 days).
T151 532-619 Sentence denotes • Comparison of remdesivir vs. local standard of care in patients with severe COVID-19.
T152 620-661 Sentence denotes Open-label RCT (NCT04252664, recruiting).
T153 662-769 Sentence denotes Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).
T154 770-859 Sentence denotes • Comparison of remdesivir vs. local standard of care in patients with moderate COVID-19.
T155 860-901 Sentence denotes Open-label RCT (NCT04292730, recruiting).
T156 902-948 Sentence denotes Primary endpoint: discharged status at day 14.
T157 949-1014 Sentence denotes • Comparison of remdesivir vs. placebo in patients with COVID-19.
T158 1015-1058 Sentence denotes Double-blind RCT (NCT04280705, recruiting).
T159 1059-1130 Sentence denotes Primary endpoint: severity rating on a 8-point ordinal scale at day 15.
T160 1131-1246 Sentence denotes • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19.
T161 1247-1305 Sentence denotes Open-label adaptive RCT (NCT04321616, not yet recruiting).
T162 1306-1376 Sentence denotes Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).
T163 1377-1546 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19.
T164 1547-1600 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T165 1601-1672 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.